endpts.com·May 12, 2026
Isomorphic Labs announced the completion of a $2.1 billion Series B funding round, reinforcing its leadership in AI-driven drug discovery and marking the second-largest fundraising in biotech history for a privately held company.
The significant $2.1 billion Series B funding round for Isomorphic Labs underscores a strong market confidence in AI-driven drug discovery, highlighting an actionable investment signal for stakeholders in healthtech and biotech sectors to closely monitor AI integration in pharmaceutical development for potential partnerships or competitive analysis.